IFN-
and BAFF overexpression is associated with etanercept treatment failure in SS
This article has no abstract so we have provided the first paragraph of the full text.
Treatment has proved difficult for Sjögren's syndrome (SS), a chronic autoimmune disease in which B cells infiltrate and destroy exocrine glands, leading to ocular and oral dryness. Although some pilot studies suggested that treatment with tumor necrosis factor (TNF) antagonists was effective in patients with primary SS, subsequent randomized, controlled trials showed no benefit.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
